Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients

BACKGROUND: Infliximab (IFX) is the first-line treatment for Crohn's disease (CD). However, the secondary loss of response (LOR) is common in IFX therapy. Therefore, non-invasive assessment of LOR in CD patients is the goal pursued by clinicians. METHODS: A multicenter study involving 181 CD pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Chao, Wang, Xingwei, Wang, Shihui, Hu, Jing, Gao, Yankun, Li, Cuiping, Li, Jianying, Wu, Xingwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161257/
https://www.ncbi.nlm.nih.gov/pubmed/37151630
http://dx.doi.org/10.1016/j.heliyon.2023.e14594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161257/
https://www.ncbi.nlm.nih.gov/pubmed/37151630
http://dx.doi.org/10.1016/j.heliyon.2023.e14594

Ejemplares similares